Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation01:37

Neural Regulation

44.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.6K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Brainstem01:19

Brainstem

7.8K
The brainstem, located inferior to the brain and superior to the spinal cord, serves as a bridge between the cerebrum and the spinal cord. It plays a vital role in relaying information and controlling critical life functions. It comprises three primary regions: the midbrain, pons, and medulla oblongata.
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson's disease.

Clinical parkinsonism & related disorders·2025
Same author

How and why the adenosine A<sub>2A</sub> receptor became a target for Parkinson's disease therapy.

International review of neurobiology·2023
Same author

Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.

Current neuropharmacology·2023
Same author

Stalevo<sup>®</sup> : A pioneering treatment for OFF periods in Parkinsons disease.

European journal of neurology·2023
Same journal

The road towards faster development of novel pharmacotherapies for persons with Parkinson's disease.

Journal of Parkinson's disease·2026
Same journal

Mortality rate, main causes of death and factors associated with higher mortality hazard in late stage Parkinson's disease.

Journal of Parkinson's disease·2026
Same journal

Abnormal motor control effort costs in Parkinson's disease patients with apathy.

Journal of Parkinson's disease·2026
Same journal

Deficits in episodic memory and executive functions in relation to CB1 receptor availability in Parkinson's disease.

Journal of Parkinson's disease·2026
Same journal

Rationale and current status of fecal microbiota transplantations for Parkinson's disease.

Journal of Parkinson's disease·2026
Same journal

Basal ganglia neurophysiological markers of non-motor symptoms in Parkinson's disease: A systematic review.

Journal of Parkinson's disease·2026
See all related articles

Related Experiment Video

Updated: Mar 23, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K

Parkinson's Inside Out

Jon Stamford1,2, Dieter Scheller2, Peter Jenner2,3

  • 1Parkinson's Movement (The Cure Parkinson's Trust).

Journal of Parkinson'S Disease
|April 1, 2016
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

23.3K

Related Experiment Videos

Last Updated: Mar 23, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

23.3K